{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Metabolic+Product+1&page=2",
    "query": {
      "intervention": "Active Metabolic Product 1",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 56,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Metabolic+Product+1&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Metabolic+Product+1&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T21:11:32.047Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03301350",
      "title": "Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 29,
      "start_date": "2017-11-07",
      "completion_date": "2022-02-07",
      "has_results": true,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-10-04T21:11:32.047Z",
      "location_count": 6,
      "location_summary": "Rockford, Illinois • Madison, Wisconsin • Milwaukee, Wisconsin + 2 more",
      "locations": [
        {
          "city": "Rockford",
          "state": "Illinois"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        },
        {
          "city": "Waukesha",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03301350"
    },
    {
      "nct_id": "NCT02286635",
      "title": "Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Deflazacort and rifampin",
          "type": "DRUG"
        },
        {
          "name": "Deflazacort and Clarithromycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PTC Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 58,
      "start_date": "2014-11",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2017-08-18",
      "last_synced_at": "2026-10-04T21:11:32.047Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02286635"
    },
    {
      "nct_id": "NCT00631007",
      "title": "A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "INT131 besylate",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone HCl",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "InteKrin Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 367,
      "start_date": "2008-02",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2010-09-13",
      "last_synced_at": "2026-10-04T21:11:32.047Z",
      "location_count": 59,
      "location_summary": "Carmichael, California • Los Angeles, California • San Diego, California + 48 more",
      "locations": [
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00631007"
    },
    {
      "nct_id": "NCT01596907",
      "title": "Treatment of Low Metabolic Rate Following Bariatric Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Morbid Obesity"
      ],
      "interventions": [
        {
          "name": "Ephedrine sulfate with caffeine",
          "type": "DRUG"
        },
        {
          "name": "cellulose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Weight Loss Surgery, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 218,
      "start_date": "2012-05",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2015-09-24",
      "last_synced_at": "2026-10-04T21:11:32.047Z",
      "location_count": 2,
      "location_summary": "Beaverton, Oregon • Portland, Oregon",
      "locations": [
        {
          "city": "Beaverton",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01596907"
    },
    {
      "nct_id": "NCT00795678",
      "title": "Chemotherapeutic Agents in Brain/Breast",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "lapatinib ditosylate",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "vinorelbine ditartrate",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2008-09",
      "completion_date": "2013-04",
      "has_results": false,
      "last_update_posted_date": "2013-08-02",
      "last_synced_at": "2026-10-04T21:11:32.047Z",
      "location_count": 2,
      "location_summary": "New York, New York • Cleveland, Ohio",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00795678"
    },
    {
      "nct_id": "NCT03640221",
      "title": "Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Ertugliflozin",
          "type": "DRUG"
        },
        {
          "name": "Hydrochlorothiazide 12.5mg",
          "type": "DRUG"
        },
        {
          "name": "Microneurography",
          "type": "DEVICE"
        },
        {
          "name": "SKNA recordings",
          "type": "OTHER"
        },
        {
          "name": "Static Handgrip",
          "type": "OTHER"
        },
        {
          "name": "Post-handgrip forearm vascular occlusion",
          "type": "OTHER"
        },
        {
          "name": "Testing of the Arterial Baroreflex Function",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "35 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2018-09-01",
      "completion_date": "2020-08-31",
      "has_results": false,
      "last_update_posted_date": "2020-01-14",
      "last_synced_at": "2026-10-04T21:11:32.047Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03640221"
    },
    {
      "nct_id": "NCT02286609",
      "title": "A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "Deflazacort",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PTC Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 16,
      "start_date": "2014-12",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2017-08-18",
      "last_synced_at": "2026-10-04T21:11:32.047Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02286609"
    },
    {
      "nct_id": "NCT00654667",
      "title": "Mechanisms of Metabolic Regulation of Resveratrol on Humans With Metabolic Syndrome",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Insulin Resistance"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Resveratrol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2007-05",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2015-03-04",
      "last_synced_at": "2026-10-04T21:11:32.047Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00654667"
    },
    {
      "nct_id": "NCT01273168",
      "title": "Endoxifen in Adults With Hormone Receptor Positive Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hormone Receptor-Positive Breast",
        "Gynecologic",
        "Desmoid",
        "Hormone Receptor-Positive Neoplasms"
      ],
      "interventions": [
        {
          "name": "Z-Endoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 40,
      "start_date": "2011-03-01",
      "completion_date": "2025-12-19",
      "has_results": false,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-10-04T21:11:32.047Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01273168"
    },
    {
      "nct_id": "NCT00288353",
      "title": "Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "aripiprazole (Abilify)",
          "type": "DRUG"
        },
        {
          "name": "ziprasidone (Geodon)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2006-01",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-10-04T21:11:32.047Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00288353"
    }
  ]
}